| Similar Articles |
|---|
 |
Pharmaceutical Executive
August 1, 2013
William Looney |
Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate.   |
Pharmaceutical Executive
June 1, 2012 |
Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory. |
Pharmaceutical Executive
February 1, 2012
Sarah Krug |
Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust. |
Pharmaceutical Executive
August 1, 2014
Ben Comer |
Pharm Exec's 2014 Emerging Pharma Leaders This year's class of 15 young executives is deeply of the moment, with wide-ranging therapeutic, business, and operational expertise. |
The Motley Fool
August 31, 2011
Brian Orelli |
Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease. |
Wall Street & Technology
May 15, 2006
Lauren Gibbons Paul |
Project and Portfolio Management Russell Investment Group uses Pacific Edge's Project Office software to aid in IT-business alignment, project management, IT portfolio management, human resource management and benefits realization analysis. |
Pharmaceutical Executive
October 1, 2005 |
Thought Leader: Room for Improvement An interview with Randal J. Kirk, founder of New River Pharmaceuticals, whose drug technology team has made it its goal to introduce safer, more efficacious and reliable models of existing franchise drugs. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
Financial Planning
March 1, 2011
Temma Ehrenfeld |
Diversification Works Investors with diversified portfolios who rode out the crash actually owned slightly bigger portfolios at the end of 2010 than they had at the peak of the market in 2007. |
Pharmaceutical Executive
June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
Chemistry World
November 11, 2013
Phillip Broadwith |
Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. |
Pharmaceutical Executive
March 1, 2009
Brittany Agro |
The New Sales Force The arms race is over, and it's time to reinvent pharma sales. Here's what forward-looking companies are experimenting with, and how it's working. |
Pharmaceutical Executive
June 1, 2012
William Looney |
From the Editor:The Connections Game As the old Broadway song goes, June is busting out all over, and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous. |
The Motley Fool
June 21, 2005
Charly Travers |
A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
Investment Advisor
February 2007
Kara Stapleton |
Small Caps On Top Again The small-cap Russell 2000 Index made a comeback in 2006. |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
BusinessWeek
October 24, 2005
Gene G. Marcial |
Undivided Attention For An ADHD Battle Sales of Shire Pharmaceuticals' Adderall XR, the leading ADHD drug, are up. |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
